Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...

However, in Wednesday's episode of The Michael Kay Show, Yankees' play-by-play announcer Michael Kay discussed Pittsburgh Pirates third baseman Ke'Bryan Hayes as a possible fit. "Ke'Bryan Hayes is ...

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...

The government, through the Ministry of Treasury, has issued special directives to pensioners nationwide on how to register for the digital pension scheme, following the launch of the online Pensioner ...

Nomura has upgraded Zydus Lifesciences Ltd. to a 'buy' from its earlier 'neutral' stance, raising the target price to Rs 1,140 from Rs 1,030, implying a potential upside of 16%. Robust earnings growth ...

Disclaimer: Please note that this list is not an official statement from the Kenya National Examinations Council (KNEC) but a compilation by TUKO.co.ke based on available data. The 2024 KCSE grading ...

Brokerage firm Nomura has upgraded shares of Zydus Lifesciences Ltd. to "buy" from its earlier rating of "hold" and also raised its price target to ₹1,140 from ₹1,030 earlier. In a note on Thursday, ...

Didacus Malowa, a journalist at TUKO.co.ke, brings over three years of experience covering politics and current affairs in Kenya. Nairobi - The release of the 2024 Kenya Certificate of Secondary ...